Finance
Cancer-drug maker reports increased net loss for fourth quarter, year
Published in Medical Letter on the CDC and FDA, April 18th, 2004
The company reported a net loss of $12,875,434, or $0.68 per basic and diluted share, for the fourth quarter of 2003, compared to a net loss of $11,404,137, or $0.61 per basic and diluted share in the fourth quarter of 2002.
The company reported no revenue for the fourth quarters ended December 31, 2003 and 2002.
The increase in the fourth-quarter 2003 net loss is a direct result of an increase in research and development expenses of $1,865,436, primarily for the development of IL13-PE38QQR, the company's lead product...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- HIV/AIDS Pathogenesis
Thiol/disulfide exchange needed for R4 HIV T-cell fusion during viral entry - Osteomyelitis
Clinicians should consider Kingella kingae in children with bone infections - Arrhythmias
Anger, frustration may trigger dangerous heart rhythms in some heart patients - Depression
FDA issues public health advisory on cautions for use of antidepressants - HIV/AIDS Epidemiology
Pacific islands face rapidly expanding HIV epidemic - Antibiotics
FDA approves amoxicillin/clavulanate potassium for oral suspension ANDA - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
